Page last updated: 2024-12-05
arsenamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Arsenamide: Proposed chemotherapeutic agent against filaria and trichomonas. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10749 |
SCHEMBL ID | 381665 |
MeSH ID | M0001720 |
Synonyms (32)
Synonym |
---|
disodium salt of the s,s-diester of p-carbamoyldithiobenzenearsonous acid with mercaptoacetic acid |
capariside |
p-(bis(carboxymethylmercapto)arsino)benzamide |
(((4-(aminocarbonyl)phenyl)arsinidine)bis(thio))biacetic acid |
bis(carboxymethylmercapto)(p-carbamylphenyl)-arsine |
thioarsenite |
thiacetarsamidum |
4-carbamylphenyl biscarboxymethylthioarsenite |
arsenamide |
acetic acid, 2,2'-(((4-(aminocarbonyl)phenyl)arsinidene)bis(thio))bis- |
dithioglycolyl p-arsenobenzamide |
benzamide, p-bis(carboxymethylmercapto)arsino- |
thiacetarsamide |
brn 3438926 |
acetic acid, mercapto-, p-carbamoyldithiobenzenearsonite (2:1) |
4-carbamylphenyl bis(carboxymethylthio)arsenite |
2-[(4-carbamoylphenyl)-(carboxymethylsulfanyl)arsanyl]sulfanylacetic acid |
531-72-6 |
unii-vmf4ely9tz |
thiacetarsamide [inn:dcf] |
3-16-00-00978 (beilstein handbook reference) |
vmf4ely9tz , |
thiacetarsamide [usp] |
thiacetarsamide [mi] |
2,2'-(((4-(aminocarbonyl)phenyl)arsinidene)bis(thio))bisacetic acid |
(((p-carbamoylphenyl)arsylene)dithio)diacetic acid |
benzamide, p-bis(carboxymethylmercapto)arsino |
thiacetarsamide [mart.] |
SCHEMBL381665 |
DTXSID10201182 |
Q4796424 |
AKOS040754184 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
"A microcomputer program using an electronic spreadsheet program was developed to calculate pharmacokinetic values of thiacetarsamide sodium, a drug used to kill the adult heartworm (Dirofilaria immitis) parasite of the dog." | ( Electronic spreadsheet program for estimating two-compartment intravenous pharmacokinetic parameters by least squares linear regression analysis. Holmes, RA; McCall, JW; Wilson, RC, 1986) | 0.27 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"The simultaneous detection of arsenic and sulfur in thioarsenicals was achieved using xenon-based collision-cell inductively coupled plasma (ICP) mass spectrometry (MS) in combination with high-performance liquid chromatography." | ( Complementary molecular and elemental detection of speciated thioarsenicals using ESI-MS in combination with a xenon-based collision-cell ICP-MS with application to fortified NIST freeze-dried urine. Caruso, JA; Conklin, SD; Creed, JT; Creed, PA; Ellis, JL; Gallawa, CM; Kubachka, KM; Young, AR, 2008) | 0.35 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Vessels were exposed to thiacetarsamide and dose-response relationships were applied to methacholine and nitroglycerin." | ( Thiacetarsamide depresses relaxation of canine pulmonary artery in vitro. Kaiser, L; Maksimowich, DS; Williams, JF, 1996) | 0.29 |
" Cumulative dose-response relations to norepinephrine, nitroglycerin, and methacholine were determined." | ( Effect of arsenical drugs on in vitro vascular responses of pulmonary artery from heartworm-infected dogs. Bell, TG; Kaiser, L; Maksimowich, DS; Williams, JF, 1997) | 0.3 |
" The CFS-like lethargy, with accompanying symptoms and signs, of the four animals obtained a complete remission after intravenous treatment with this drug at low dosage (0." | ( Chronic fatigue syndrome in horses: diagnosis and treatment of 4 cases. Tarello, W, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (72)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 42 (58.33) | 18.7374 |
1990's | 12 (16.67) | 18.2507 |
2000's | 12 (16.67) | 29.6817 |
2010's | 3 (4.17) | 24.3611 |
2020's | 3 (4.17) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 9.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.91) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (6.49%) | 6.00% |
Case Studies | 7 (9.09%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 65 (84.42%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |